KALA BIO, Inc. (NASDAQ:KALA) Major Shareholder Buys $1,999,999.96 in Stock

KALA BIO, Inc. (NASDAQ:KALA) major shareholder Bros. Advisors Lp Baker purchased 310,559 shares of the business’s stock in a transaction on Monday, December 30th. The stock was purchased at an average cost of $6.44 per share, with a total value of $1,999,999.96. Following the acquisition, the insider now owns 1,083,398 shares in the company, valued at approximately $6,977,083.12. This represents a 40.18 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

KALA BIO Price Performance

Shares of NASDAQ:KALA traded up $0.07 during midday trading on Tuesday, reaching $6.94. 25,347 shares of the company’s stock were exchanged, compared to its average volume of 77,397. The company has a debt-to-equity ratio of 3.18, a quick ratio of 2.15 and a current ratio of 2.15. The company’s 50 day simple moving average is $6.60 and its two-hundred day simple moving average is $6.24. KALA BIO, Inc. has a 12 month low of $4.21 and a 12 month high of $9.25. The firm has a market capitalization of $31.99 million, a PE ratio of -0.56 and a beta of -2.15.

KALA BIO (NASDAQ:KALA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.93) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.43) by $0.50. Equities research analysts expect that KALA BIO, Inc. will post -10.84 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $15.00 price objective on shares of KALA BIO in a research report on Friday, November 15th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in KALA BIO stock. SR One Capital Management LP bought a new position in KALA BIO, Inc. (NASDAQ:KALA) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO comprises about 1.0% of SR One Capital Management LP’s investment portfolio, making the stock its 9th biggest holding. SR One Capital Management LP owned 15.76% of KALA BIO at the end of the most recent reporting period. Institutional investors own 24.61% of the company’s stock.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.